Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq
15. Oktober 2024 16:05 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that its Series B Preferred Stock investors, Ampersand...
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting
20. Oktober 2022 16:28 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests
22. Februar 2022 09:00 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, announced today that the...
Interpace Biosciences Announces CFO Leadership Transition
04. Februar 2021 16:42 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has...
Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021
20. Januar 2021 15:38 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast...
Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan
20. Januar 2021 08:30 ET
|
Interpace Biosciences, Inc.
Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior YearEstimates Fourth Quarter Net Revenue range of $9.0 million -...
Interpace Biosciences Announces Second Quarter 2020 Financial and Business Results
20. Oktober 2020 08:00 ET
|
Interpace Biosciences, Inc.
Year to Date Net Revenue of $14.6 Million Up 19% vs Prior Year; Second Quarter Net Revenue of $5.4 Million Publication of Seminal Clinical Validation Study Related to Thyroid Products ...
Interpace Announces Extension of LabCorp Agreement
24. Februar 2020 06:55 ET
|
Interpace Biosciences, Inc.
ThyGeNEXT and ThyraMIR Collaboration Extended for Another Two Years PARSIPPANY, NJ, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that its...
Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility
04. November 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Clinical Data Highlights the Utility of ThyGeNEXT® and ThyraMIR® PARSIPPANY, NJ, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Interpace Group (NASDAQ: IDXG) Interpace Diagnostics announced today the...
Interpace Named to ‘Most Admired Companies’ List
15. Oktober 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The...